CTI 2024 | IACH Chairman Dr. Mohamad Mohty: Updates on the Latest Treatment Advances in GVHD

CTI 2024 | IACH Chairman Dr. Mohamad Mohty: Updates on the Latest Treatment Advances in GVHD

From November 14th to 17th, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was grandly held in Hangzhou, China, gathering top experts, scholars, and industry leaders in the field of global cell therapy and immune therapy. The conference served not only as an international platform for academic exchange but also as an important window to showcase the latest scientific research and promote the development of the field. During this conference, "Hematology Frontier" specially invited the conference chair and the chairman of the International Academy for Clinical Hematology (IACH), Dr. Mohamad Mohty from Sorbonne University , France, to share his insights on the latest treatment advances in Graft-Versus-Host Disease (GVHD), aiming to provide valuable insights for clinicians and researchers and to explore the future direction of GVHD treatment.
ASH 2024 | Dr. He Huang’s Team Secures 8 Oral Presentations, Showcasing Chinese Excellence on the Global Stage

ASH 2024 | Dr. He Huang’s Team Secures 8 Oral Presentations, Showcasing Chinese Excellence on the Global Stage

The highly anticipated 66th Annual Meeting of the American Society of Hematology (ASH) will take place in San Diego, USA, from December 7 to 10, 2024. Renowned as one of the largest and most comprehensive international academic events in hematology, the ASH Annual Meeting serves as a premier platform for advancing the frontiers of the discipline. This global gathering attracts thousands of experts and scholars who come together to exchange cutting-edge research and breakthroughs in the field.
Dr. Yishan Ye on Donor Selection Trends: Insights from China’s Allogeneic Hematopoietic Stem Cell Transplantation Practice and the EBMT-China

Dr. Yishan Ye on Donor Selection Trends: Insights from China’s Allogeneic Hematopoietic Stem Cell Transplantation Practice and the EBMT-China

From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was held in Hangzhou, China, attracting leading experts, scholars, and industry leaders in cellular and immune therapies. This international platform not only fosters academic exchange but also showcases the latest research breakthroughs and drives progress in the field. During the conference, Dr. Yishan Ye from The First Affiliated Hospital of Zhejiang University School of Medicine shared his insights in an interview with Hematology Frontier. He discussed the principles of donor selection in allogeneic hematopoietic stem cell transplantation (allo-HCT) and the findings from the EBMT-China collaboration. Here is the interview in full.
CTI 2024 | Professor Li Tang: Promising Horizons for CAR-T and mRNA Gene Therapy

CTI 2024 | Professor Li Tang: Promising Horizons for CAR-T and mRNA Gene Therapy

From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) took place in Hangzhou, China. This global event brought together leading experts, scholars, and industry pioneers in cellular and immune therapies, serving as both an academic platform and a showcase for the latest research breakthroughs. During the conference, Hematology Frontier launched the special column “Professor, Please Answer,” featuring on-the-spot interviews with prominent professors to capture their insights and visions for the future of the field. In this edition, we share the inspiring perspectives of Professor Li Tang from École Polytechnique Fédérale de Lausanne (EPFL), Switzerland.
CTI 2024丨Prof. Xi Zhang: New Developments and Challenges in Chronic Graft-Versus-Host Disease

CTI 2024丨Prof. Xi Zhang: New Developments and Challenges in Chronic Graft-Versus-Host Disease

From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) took place in Hangzhou, China, bringing together global leaders in cellular and immune therapies. This prestigious event served as a platform for academic exchange and a showcase for cutting-edge research in the field. During the conference, Prof. Xi Zhang from the Department of Hematology at Xinqiao Hospital , Army Medical University shared key insights on chronic graft-versus-host disease (cGVHD).
How I Treat丨Prof. Fengkui Zhang: My Approach to Treating Severe Aplastic Anemia

How I Treat丨Prof. Fengkui Zhang: My Approach to Treating Severe Aplastic Anemia

Severe aplastic anemia (AA) remains a significant therapeutic challenge despite progress in its diagnosis and treatment. Issues such as difficulty in donor matching, side effects of immunosuppressive therapy (IST), and suboptimal hematologic responses demand continued exploration of innovative solutions. Prof. Fengkui Zhang of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences delivered a compelling presentation on treating severe aplastic anemia. In an interview with Hematology Frontier, Prof. Zhang shared insights into managing refractory aplastic anemia and the latest treatment advancements.